Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York, NY will investigate the potential use of Kazia’s investigational new drug, GDC-0084, in combination with radiotherapy in a phase I clinical trial for cancer that has spread to the brain (brain metastases and leptomeningeal metastases). This research will explore a new use of GDC-0084 and will run concurrently with other ongoing studies in different forms of brain cancer.
Comments Off on Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer
Tags:Aussie, Australia, Australian, biotechnology, brain, cancer, drug, investigation, New York, oncology, research, trial, U.S., York
Buy us a coffee Why?
Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don't put up a paywall – we beleive in free public access to information. Although underresourced & primarily volunteer-based, we endeavour to provide the community with real-time access to true unfiltered news directly from the firsthand sources. Our goal and mission is to provide free and alternative access to impartial information, fighting media monopolization and adhering to honesty, neutrality, fairness, transparency and independence in collection and dissemination of information. It is a bumpy road with all sorties of difficulties. (Media ownership in Australia is one of the most concentrated in the world (more on this!). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate. If you like what we do & would like to buy us a coffee (or lots of coffees), please know it's greatly appreciated. All donations are kept completely private and confidential. Thank you very much in advance!